Marburg hemorrhagic fever epidemiology and demographics

	Marburg hemorrhagic fever Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Marburg hemorrhagic fever from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Marburg hemorrhagic fever epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Marburg hemorrhagic fever epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Marburg hemorrhagic fever epidemiology and demographics
CDC on Marburg hemorrhagic fever epidemiology and demographics
Marburg hemorrhagic fever epidemiology and demographics in the news
Blogs on Marburg hemorrhagic fever epidemiology and demographics
Directions to Hospitals Treating Marburg hemorrhagic fever
Risk calculators and risk factors for Marburg hemorrhagic fever epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief:

Overview

Recorded cases of Marburg hemorrhagic fever disease are rare. Hence it is difficult to obtain accurate data of incidence and prevalence of Marburg hemorrhagic fever.

The first documented outbreak of filovirus disease occurred in 1967 when there were three concurrent episodes of lethal MARV infections in Marburg and Frankfurt, Germany and in Belgrade (in the former Yugoslavia) among laboratory workers exposed to blood and tissue products of African green monkeys imported from Uganda.
Secondary transmission to medical staff and family members was also documented.
In total, 31 patients became infected, and 7 of these patients died.
During the next 2 decades, Marburg hemorrhagic fever was associated with sporadic, isolated, usually fatal cases among residents and travelers in southeast Africa.
In 1998 to 2000, there was a prolonged outbreak involving 154 cases of MARV-associated hemorrhagic fever in Durba, Democratic Republic of the Congo (DRC) that was associated with individuals working in an underground gold mine.
The largest and most lethal MARV outbreak to date occurred in 2004 to 2005 in northern Angola.
- This outbreak involved 252 cases, with a case-fatality rate of 90%.
Between 2007 and 2012, several small episodes of MARV-associated disease were reported in Uganda, with one case being exported to the United States and one to the Netherlands.
In October 2014, a single case of Marburg hemorrhagic fever was reported in Uganda.

Case fatality rates in marburg hemorrhagic fever outbreaks have ranged from 23% to 90%.

Patients of all age groups may develop marburg hemorrhagic fever.
Marburg hemorrhagic fever commonly affects younger individuals less than 5 years old and adults >50 years old compared to normal age groups. younger than/older than [number of years] years of age.

There is no racial predilection to marburg hemorrhagic fever.

Marburg hemorrhagic fever affects men and women equally.